{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:09:43Z","timestamp":1787738983974,"version":"build-2784847793"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"03","funder":[{"name":"German Research Council","award":["GEPRIS project: 413584448"],"award-info":[{"award-number":["GEPRIS project: 413584448"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) are nephroprotective in patients with recompensated acute and chronic heart failure (HF) and chronic kidney disease, but their potential influence during cardiac surgery is unclear. Currently, discontinuation of SGLT2i at least 2 days before surgery is recommended.<\/jats:p>\n                  <jats:p>Between March 2022 and December 2023, 53 cardiac surgical patients on SGLT2i therapy in addition to standard medical treatment for HF were compared with 447 other HF patients from the same period. After 1:1 covariate adjustment, 33 patients with SGLT2i treatment were matched with 33 controls. The primary endpoint was a change in estimated glomerular filtration rate (eGFR) 36\u2009hours after surgery. Secondary endpoints were changes in eGFR, cumulative urine output, diuretic efficacy, and albuminuria over seven postoperative days.<\/jats:p>\n                  <jats:p>Mean baseline eGFR was similar between the groups (p\u2009=\u20090.973). Thirty-six hours postoperatively, eGFR was significantly higher in the SGLT2i group by a mean difference (MD) of 11.8\u2009mL\/min (95% CI [3.12\u201320.44]; p\u2009=\u20090.009) compared with the control group. The mean urinary albumin level was 18.1\u2009mg\/mL lower in the SGLT2i group (95% CI [\u221242.5\u20136.33]; p\u2009=\u20090.143). There were numerically positive changes in urine output and diuretic efficacy in the SGLT2i group without significant difference: MD 131.4\u2009mL\/24\u2009hours (95% CI [\u2212366.7\u2013629.5]; p\u2009=\u20090.600) and MD 11.3\u2009mL\/mg (95% CI [\u221212.2\u201334.7]; p\u2009=\u20090.301), respectively, although the dosage of diuretics was higher in controls (30.6\u2009\u00b1\u200943.7 vs. 51.3\u2009\u00b1\u2009130.1\u2009mg\/24\u2009hours; p\u2009=\u20090.268, respectively).<\/jats:p>\n                  <jats:p>SGLT2i may have nephroprotective effects in patients undergoing heart surgery with extracorporeal circulation. More evidence is needed to determine whether SGTL2i needs to be discontinued before surgery.<\/jats:p>","DOI":"10.1055\/a-2616-4962","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T20:14:19Z","timestamp":1747772059000},"page":"220-231","source":"Crossref","is-referenced-by-count":5,"title":["Impact of SGLT2 Inhibitor Therapy on Patients Undergoing Cardiac Surgery"],"prefix":"10.1055","volume":"74","clinical-trial-number":[{"clinical-trial-number":"nct06365827","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-3117","authenticated-orcid":false,"given":"Zulfugar T.","family":"Taghiyev","sequence":"additional","affiliation":[{"name":"Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili-Marie","family":"Beier","sequence":"additional","affiliation":[{"name":"Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Leweling","sequence":"additional","affiliation":[{"name":"Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Gunkel","sequence":"additional","affiliation":[{"name":"Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Mike","family":"Sadowski","sequence":"additional","affiliation":[{"name":"Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Assmus","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Giessen, Giessen, Hessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Boening","sequence":"additional","affiliation":[{"name":"Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/icvts\/ivu014","article-title":"Cardiac surgery-associated acute kidney injury","volume":"18","author":"M Vives","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)","volume":"17","author":"J A Kellum","year":"2013","journal-title":"Crit Care"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000353134","article-title":"Cardiac surgery-associated acute kidney injury","volume":"3","author":"H Mao","year":"2013","journal-title":"Cardiorenal Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12916-023-03215-9","article-title":"Prediction of acute kidney injury incidence following acute type A aortic dissection surgery with novel biomarkers: a prospective observational study","volume":"21","author":"Z Wang","year":"2023","journal-title":"BMC Med"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2215\/CJN.00240605","article-title":"Acute kidney injury associated with cardiac surgery","volume":"1","author":"M H Rosner","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000349969","article-title":"Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI)","volume":"182","author":"M Haase","year":"2013","journal-title":"Contrib Nephrol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13054-016-1352-z","article-title":"Acute kidney injury following cardiac surgery: current understanding and future directions","volume":"20","author":"J B O'Neal","year":"2016","journal-title":"Crit Care"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5527\/wjn.v4.i2.196","article-title":"Renal dopaminergic system: Pathophysiological implications and clinical perspectives","volume":"4","author":"M R Choi","year":"2015","journal-title":"World J Nephrol"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10741-011-9235-5","article-title":"Pharmacological therapies for the prevention of acute kidney injury following cardiac surgery: A systematic review","volume":"16","author":"N N Patel","year":"2011","journal-title":"Heart Fail Rev"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1213\/01.ANE.0000086727.42573.A8","article-title":"Mannitol and dopamine in patients undergoing cardiopulmonary bypass: A randomized clinical trial","volume":"97","author":"O V Carcoana","year":"2003","journal-title":"Anesth Analg"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1081\/JDI-100103493","article-title":"Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine","volume":"23","author":"M G Dehne","year":"2001","journal-title":"Ren Fail"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1681\/ASN.V11197","article-title":"Lack of renoprotective effects of dopamine and furosemide during cardiac surgery","volume":"11","author":"A Lassnigg","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"05","key":"ref13","first-page":"397","article-title":"Low dose dopamine infusion reduces renal tubular injury following cardiopulmonary bypass surgery","volume":"14","author":"M Sumeray","year":"2001","journal-title":"J Nephrol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1010-7940(02)00246-4","article-title":"Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: Science or fiction?","volume":"22","author":"E B Woo","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"issue":"01","key":"ref15","first-page":"25","article-title":"Renal dose dopamine in open heart surgery. Does it protect renal tubular function?","volume":"43","author":"S Yavuz","year":"2002","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"ref16","first-page":"PI45","article-title":"Effect of combined dopamine and diltiazem on renal function after cardiac surgery","volume":"8","author":"S Yavuz","year":"2002","journal-title":"Med Sci Monit"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1213\/ANE.0000000000006286","article-title":"The Society of Thoracic Surgeons\/Society of Cardiovascular Anesthesiologists\/American Society for Extracorporeal Technology Clinical Practice Guidelines for the Prevention of Adult Cardiac Surgery-Associated Acute Kidney Injury","volume":"136","author":"J R Brown","year":"2023","journal-title":"Anesth Analg"},{"issue":"04","key":"ref18","first-page":"241","article-title":"SGLT2-inhibitors: What is new? [in German.]","volume":"16","author":"E Dumann","year":"2021","journal-title":"Nephrologe"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"D C Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"ref20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"M Packer","year":"2022","journal-title":"Circulation"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"K M Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"P M Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","article-title":"Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: A systematic review","volume":"38","author":"M Murton","year":"2021","journal-title":"Adv Ther"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"D W Cockcroft","year":"1976","journal-title":"Nephron J"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"A Piperidou","year":"2019","journal-title":"J Hypertens"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12181-023-00598-0","article-title":"Sodium-glukose-transporter 2-Hemmer bei herzinsuffizienz mit erhaltener auswurffraktion","volume":"17","author":"M B\u00f6hm","year":"2023","journal-title":"Kardiologie"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial","volume":"141","author":"M N Kosiborod","year":"2020","journal-title":"Circulation"},{"issue":"36","key":"ref28","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"M Serenelli","year":"2020","journal-title":"Eur Heart J"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"I EP Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"111811","DOI":"10.1016\/j.jclinane.2025.111811","article-title":"The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study","volume":"103","author":"L IP Snel","year":"2025","journal-title":"J Clin Anesth"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"J B Buse","year":"2020","journal-title":"Diabetes Care"},{"issue":"37","key":"ref33","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"T A McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"14","key":"ref34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"M C Petrie","year":"2020","journal-title":"JAMA"}],"container-title":["The Thoracic and Cardiovascular Surgeon"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2616-4962.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:33:39Z","timestamp":1774395219000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2616-4962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":34,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,3,24]]},"published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2616-4962","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0171-6425","1439-1902"],"issn-type":[{"value":"0171-6425","type":"print"},{"value":"1439-1902","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,20]]},"published":{"date-parts":[[2025,5,20]]}}}